 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || anti-CD19-CAR / Kecellitics Biotech
Trial completion date, Trial primary completion date, CAR T-Cell Therapy: Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia (clinicaltrials.gov) - Dec 1, 2022
P1, N=100, Not yet recruiting, Sponsor: Kecellitics Biotech Company Ltd
Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023
- | anti-CD19-CAR / Kecellitics Biotech
Journal: Anti-CD19 CAR T as a feasible therapy for refractory/relapsed mixed phenotype acute leukemia patients. (Pubmed Central) - Aug 31, 2022
Trial completion date: Aug 2022 --> Aug 2024 | Trial primary completion date: Aug 2021 --> Aug 2023 No abstract available
- | anti-CD19-CAR / Kecellitics Biotech
New P1 trial, CAR T-Cell Therapy: Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia (clinicaltrials.gov) - Sep 23, 2019
P1, N=100, Not yet recruiting, Sponsor: Kecellitics Biotech Company Ltd